Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods-Reference-Cited by-同舟云学术

Mechanistic Insights into a CDK9 Inhibitor Via Orthogonal Proteomics Methods

Published:2021-12-25 Issue:1 Volume:17 Page:54-67
ISSN:1554-8929
Container-title:ACS Chemical Biology
language:en
Short-container-title:ACS Chem. Biol.

Author:

Hendricks J. Adam¹,Beaton Nigel²,Chernobrovkin Alexey³,Miele Eric¹,Hamza Ghaith M.¹⁴,Ricchiuto Piero⁵,Tomlinson Ronald C.¹,Friman Tomas³,Borenstain Cassandra¹,Barlaam Bernard⁶^ORCID,Hande Sudhir⁷,Lamb Michelle L.⁷^ORCID,De Savi Chris⁷,Davies Rick⁵,Main Martin⁵,Hellner Joakim³,Beeler Kristina²,Feng Yuehan²,Bruderer Roland²^ORCID,Reiter Lukas²^ORCID,Molina Daniel Martinez³,Castaldi M. Paola¹^ORCID

Affiliation:

1. Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States

2. Biognosys AG, Wagistrasse 21, Schlieren 8952, Switzerland

3. Pelago Bioscience AB, Banvaktsvägen 20, Solna 17148, Sweden

4. Molecular, Cellular and Biomedical Sciences, University of New Hampshire, Durham, New Hampshire 03824, United States

5. Discovery Sciences, AstraZeneca, Cambridge CB4 0WG, U.K.

6. Oncology R&D, AstraZeneca, Cambridge CB4 0WG, U.K.

7. Oncology R&D, Boston, Massachusetts 02451, United States

Publisher

American Chemical Society (ACS)

Subject

Molecular Medicine,General Medicine,Biochemistry